4/8/2019 | BKCVHY | S&P upgrades Horizon
|
2/28/2019 | CV | Market Commentary: LivePerson oversubscribed, expands on debut; Applied Optoelectronics eyed; Novavax tanks
|
8/8/2018 | CV | Market Commentary: Market eyes Rapid7, NII Holdings; Tesla dominates; Horizon on the rise
|
11/27/2017 | CV | Market Commentary: Square tumbles after record high, health care companies active in post-holiday lull
|
5/8/2017 | CV | Market Commentary: DexCom, Kaman, Becton Dickinson enter market; Horizon falters as guidance lowered; Cobalt up
|
5/8/2017 | CV | Market Commentary: Morning Commentary: DexCom, Kaman, Becton Dickinson plan to tap market; Horizon falters
|
10/19/2016 | BKCVDDEMIGPV | Market Commentary: NGL Energy, Horizon deals price; new NGL notes jump; Sprint on tap; coal names catch fire
|
10/14/2016 | BKCVDDEMIGPV | Market Commentary: Primary quiet to close out $770 million week; UCP slates deal; Lions Gate, Warner continue rise
|
10/13/2016 | BKCVDDEMIGPV | Market Commentary: Warner Music, Lions Gate price, gain; Horizon shops deal; Rackspace rises; funds lose $72 million
|
7/1/2016 | CV | Market Commentary: Convertibles quiet ahead of holiday; Exelixis in line; Softbank/Alibaba mandatories better
|
5/12/2016 | CV | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
5/12/2016 | CV | Market Commentary: Morning Commentary: Qihoo 360 convertibles, shares ease; Horizon Pharma, Jazz bonds down
|
5/9/2016 | CV | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
3/15/2016 | CV | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
2/29/2016 | CV | Market Commentary: Horizon Pharma contracts as shares drop; Priceline adds in line; Newmont expands slightly
|
2/29/2016 | CV | Market Commentary: Morning Commentary: Priceline adds in line; Newmont expands; Horizon contracts as shares drop
|
12/11/2015 | CV | Market Commentary: Convertibles down in line with lower equities; Horizon Pharma falters; SunEdison steady
|
12/3/2015 | BKBWCVHYLW | Horizon Pharma has 4.6x leverage, could go to 6x for right opportunity
|
11/11/2015 | CV | Market Commentary: Aceto flat to lower outright, adds on swap; SunEdison extends slide; Horizon Pharma drops
|
11/9/2015 | CV | Market Commentary: Iconix, Horizon Pharma regain ground after steep losses; Priceline 1% expands on swap
|
11/6/2015 | CV | Market Commentary: Iconix Brand collapses on accounting restatements, lowered guidance; HomeAway drops back
|
10/23/2015 | CV | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
10/23/2015 | CV | Market Commentary: Morning Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings
|
10/22/2015 | CV | Market Commentary: Intel’s 2.95% convertible sees outright sellers; Proofpoint sees better buyers on earnings
|
10/22/2015 | CV | Market Commentary: Morning Commentary: Horizon Pharma lower again; valuations steady; Proofpoint sees better buyers
|
10/21/2015 | CV | Market Commentary: SanDisk lower on swap after takeout news; Micron lower outright; Horizon slumps on swap
|
10/20/2015 | CV | Market Commentary: SanDisk 0.5% contracts on swap as SanDisk 1.5% rides higher; Horizon Pharma, Tesla drop
|
9/29/2015 | CV | Market Commentary: Convertibles improve; Horizon Pharma paper weakens amid Depomed battle; Chesapeake lower
|
9/29/2015 | CV | Market Commentary: Morning Commentary: Convertibles head to higher ground; Horizon paper weakens amid Depomed battle
|
9/22/2015 | CV | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
7/20/2015 | CV | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
7/7/2015 | CV | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
7/7/2015 | CV | Market Commentary: Morning Commentary: Medicines convertibles higher in active trade; Depomed deflects Horizon offer
|
6/4/2015 | CV | Market Commentary: Rate-sensitive convertible notes under pressure; Frontier Communications, Anadarko on tap
|
4/21/2015 | BKCVHY | S&P: Horizon Pharma loan BB-, notes B-, convertibles CCC+
|
4/16/2015 | CV | Market Commentary: SanDisk lower outright, edges up on swap; Teva below parity; planned Pernix looks cheap
|
4/13/2015 | CV | Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
|
3/30/2015 | CV | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
3/30/2015 | CV | Market Commentary: Morning Commentary: Horizon Pharma jumps outright; health care bid remains strong; Intel active
|
3/19/2015 | CV | Market Commentary: Tesla Motors up in active trade; Chesapeake mostly quiet with shares down; primary stays hushed
|
3/16/2015 | CVLM | Horizon Pharma to exchange $32.2 million more notes for stock, cash
|
3/13/2015 | CV | Horizon Pharma greenshoe lifts 2.5% exchangeables to $400 million
|
3/6/2015 | CV | Market Commentary: New convertibles from Horizon Phama, Consolidated-Tamoka, InterDigital expand on swap
|
3/6/2015 | CV | Market Commentary: Morning Commentary: New Horizon, Consolidated deals up 2 points on hedge; new InterDigital gains
|
3/6/2015 | CV | New Issue: Horizon Pharma prices upsized $350 million seven-year exchangeables at 2.5%, up 37.5%
|
3/5/2015 | CV | Market Commentary: NXP Semiconductors expands; Cheniere extends gains; Horizon Pharma deal looks ‘cheap’
|
3/5/2015 | CV | Market Commentary: Morning Commentary: Cheniere extends gains; planned Horizon Pharma deal looks ‘cheap’
|
3/4/2015 | CV | Market Commentary: Cheniere expands on hedge; new Gogo upsized, trades flattish; three deals join calendar
|
3/4/2015 | CV | Horizon Pharma offers $300 million seven-year exchangeables at 2.25%-2.75%, up 27.5%-32.5%
|
12/15/2014 | CVLM | Horizon Pharma to exchange $11 million more notes for stock, cash
|
11/26/2014 | CVLM | Horizon Pharma to settle $8.6 million converted notes in stock, cash
|
10/24/2014 | CVLM | Horizon Pharma to settle $60.9 million converted notes in stock, cash
|